Immuneering Corp (IMRX) Form 8-K — Oct 29, 2026
Immuneering (Nasdaq: IMRX) reported Q3 2026 results with a net loss of $24.2 million ($0.37 per share) and $166.1 million in cash, providing runway into the fourth quarter of 2028. Clinically, the Phase 2 pancreatic cancer trial follow-up is being extended because patients on atebimetinib + mGnP are living longer than projected, with updated data (N=55) expected in the first half of 2027. The company previously reported a 17.3-month median overall survival at ASCO, which it calls unprecedented for MEK inhibitors.
Key figures
- Cash Position
- 166100000
- Cash runway
- into Q4 2028
- Phase2 pdac n
- 55
- Net loss q3 2025
- 15000000
- Ga expense q3 2025
- 4500000
- Ga expense q3 2026
- 5100000
- Rd expense q3 2025
- 10900000
- Rd expense q3 2026
- 20700000
- Cash position dec 2025
- 217000000
- Phase3 topline guidance
- mid-2028, potentially accelerated
- Phase3 enrollment target
- 570
- Phase3 prior enrollment target
- 510
- Ascot median overall survival months
- 17.3
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.